Výsledky vyhledávání - "Ryan Kenneth Nowak"

Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study

Autor: Kathryn A. Gold, Ezra E.W. Cohen, Christopher D. Fischer, Christopher Joseph Sumey, Ryan Kenneth Nowak, Steven McGraw, Paul A. Thompson, William C. Spanos, Juan Luis Callejas-Valera, Ashley Wayne Jensen, Miran J. Blanchard, Michele Lohr, Lora Jane Black, Mark M. Gitau, Julie Bykowski, Steven Francis Powell, Christie Ellison, John H. Lee

Publikováno v: J Clin Oncol
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 21

PURPOSE Pembrolizumab is a humanized monoclonal antibody that blocks interaction between programmed death receptor-1 (PD-1) and its ligands (PD-L1, PD-L2). Although pembrolizumab is approved for recurrent/metastatic head and neck squamous cell carcin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19be478bffc9e3635bed30f4041686a2
https://europepmc.org/articles/PMC7365766/

Zobrazit plný text záznamu

Implementation of a standardized approach to borderline resectable pancreatic cancer in a community oncology program

Autor: Thavam C. Thambi-Pillai, Preston D. Steen, Peter Kurniali, Michael D. Keppen, Steven Francis Powell, Robert Sticca, Daniel Tuvin, Mark M. Gitau, Miran J. Blanchard, Jonathan Bleeker, Gary Timmerman, Christopher Joseph Sumey, Steven McGraw, Miroslaw Mazurczak, Michele Lohr, Ryan Kenneth Nowak

Publikováno v: Journal of Clinical Oncology. 36:493-493

493 Background: Treatment paradigms for borderline resectable pancreatic cancer (BRPC) continue to evolve with increasing use of neoadjuvant chemotherapy (NAC) and chemoradiation (NACR). Variations in the definition of BRPC and in neoadjuvant approac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1adcf474775370b1aea3789662714cc8
https://doi.org/10.1200/jco.2018.36.4_suppl.493

Zobrazit plný text záznamu

Safety of pembrolizumab with chemoradiation (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN)

Autor: Michele Lohr, Ezra E.W. Cohen, William C. Spanos, Andrew M Terrell, Lora Jane Black, Steven Francis Powell, Paul A. Thompson, Mark M. Gitau, Christopher Joseph Sumey, Steven McGraw, Ashley W. Jensen, Ryan Kenneth Nowak, Kathryn A. Gold, Miran J. Blanchard, John H. Lee, John Reynolds, Christie Ellison

Publikováno v: Journal of Clinical Oncology. 35:6011-6011

6011 Background: Pembrolizumab (pembro) is a humanized monoclonal antibody that blocks the programmed death receptor-1 (PD-1) interaction with its ligands (PD-L1, PD-L2). While pembro is approved for platinum-refractory, recurrent/metastatic SCCHN, i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3d71bd30e6021f3b99d70bef7200b3c4
https://doi.org/10.1200/jco.2017.35.15_suppl.6011

Zobrazit plný text záznamu

Phase IB study of pembrolizumab in combination with chemoradiotherapy (CRT) for locally-advanced squamous cell carcinoma of the head and neck (LA-SCCHN)

Autor: Assuntina G. Sacco, Michele Lohr, Susan E. Puumala, William C. Spanos, Steven Francis Powell, Lora Jane Black, Christie Ellison, John H. Lee, Mark M. Gitau, Ezra E.W. Cohen, Jonathan D. Cheng, Ashley Wayne Jensen, Ryan Kenneth Nowak

Publikováno v: Journal of Clinical Oncology. 34:TPS6107-TPS6107

TPS6107Background: The host immune response is critical for the clearance of SCCHN during CRT. Recent translational research has demonstrated that the programmed death receptor 1 (PD-1) and its lig...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c8caaef474b1931c3ccca57ddead5acf
https://doi.org/10.1200/jco.2016.34.15_suppl.tps6107

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání